Article Abstract

De novo hepatocellular carcinoma in the context of new direct acting antivirals: time seems to start talking

Authors: Ezequiel Mauro, Gonzalo Crespo


For years, hepatitis C virus (HCV) infection has been considered the main cause of liver cirrhosis and hepatocellular carcinoma (HCC) (1). The development of new treatments with direct acting antivirals (DAAs), that achieve very high rates of sustained virologic response (SVR) and thus viral eradication, is probably the most significant advance in the field of Hepatology in the last 50 years (2).